GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDS Biotechnology Corp (NAS:PDSB) » Definitions » ROIC %

PDS Biotechnology (PDS Biotechnology) ROIC % : -1,677.87% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is PDS Biotechnology ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. PDS Biotechnology's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2023 was -1,677.87%.

As of today (2024-04-28), PDS Biotechnology's WACC % is 13.69%. PDS Biotechnology's ROIC % is -2989.99% (calculated using TTM income statement data). PDS Biotechnology earns returns that do not match up to its cost of capital. It will destroy value as it grows.


PDS Biotechnology ROIC % Historical Data

The historical data trend for PDS Biotechnology's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PDS Biotechnology ROIC % Chart

PDS Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -484.48 -2,500.34 -2,625.57 -5,650.29 -1,551.48

PDS Biotechnology Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9,032.27 -5,052.01 -7,595.45 -9,137.89 -1,677.87

Competitive Comparison of PDS Biotechnology's ROIC %

For the Biotechnology subindustry, PDS Biotechnology's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PDS Biotechnology's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PDS Biotechnology's ROIC % distribution charts can be found below:

* The bar in red indicates where PDS Biotechnology's ROIC % falls into.



PDS Biotechnology ROIC % Calculation

PDS Biotechnology's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-43.045 * ( 1 - 3.17% )/( (0.81599999999999 + 4.557)/ 2 )
=-41.6804735/2.6865
=-1,551.48 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=77.008 - 9.533 - ( 73.82 - max(0, 9.821 - 76.48+73.82))
=0.81599999999999

PDS Biotechnology's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2023 is calculated as:

ROIC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-41.628 * ( 1 - 0% )/( (0.405 + 4.557)/ 2 )
=-41.628/2.481
=-1,677.87 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PDS Biotechnology  (NAS:PDSB) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, PDS Biotechnology's WACC % is 13.69%. PDS Biotechnology's ROIC % is -2989.99% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


PDS Biotechnology ROIC % Related Terms

Thank you for viewing the detailed overview of PDS Biotechnology's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


PDS Biotechnology (PDS Biotechnology) Business Description

Traded in Other Exchanges
Address
25B Vreeland Road, Suite 300, Florham Park, NJ, USA, 07932
PDS Biotechnology Corp operates as a clinical-stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Executives
Spencer D. Brown officer: Senior VP, General Counsel 25B VREELAND ROAD, SUITE 300, FLORHAM PARK NJ 07932
Matthew C Hill officer: Chief Financial Officer C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
Delyle W Bloomquist director, 10 percent owner RAYONIER ADVANCED MATERIALS INC., 1301 RIVERPLACE BLVD., SUITE 2300, JACKSONVILLE FL 32207
Voorhees Seth Van officer: Chief Financial Officer 12 HARVEY DRIVE, SHORT HILLS NJ 07078
Kamil Ali-jackson director C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
Gregory Gene Freitag director 13631 PROGRESS BLVD., ALACHUA FL 32615
Stephen C. Glover director 108 DOCKSIDE CIRCLE, WESTON FL 33327
Otis W Brawley director 5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Michael N. King officer: Interim Chief Financial Office 303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Ilian Iliev director 303 A COLLEGE ROAD EAST, PRINCETON NJ 08540
Janetta Trochimiuk officer: Principal Accounting Officer 303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Richard Sykes director C/O PDS BIOTECHNOLOGY CORPORATION, 25B VREELAND ROAD, FLORHAM PARK NJ 07932
Frank Bedu-addo director, 10 percent owner, officer: President/CEO 300 CONNELL DRIVE, SUITE 400, BERKELEY HEIGHTS NJ 07922
Lauren Wood officer: Chief Medical Officer 300 CONNELL DRIVE, SUITE 4000, BERKELEY HEIGHTS NJ 07922
Gregory Conn officer: Chief Scientific Officer 300 CONNELL DRIVE, SUITE 4000, BERKELEY HEIGHTS NJ 07922

PDS Biotechnology (PDS Biotechnology) Headlines

From GuruFocus